300
Participants
Start Date
March 6, 2019
Primary Completion Date
July 31, 2021
Study Completion Date
August 31, 2021
Direct-acting antiviral agents
The initial DAA treatment and its dose for all patients is determined by the infectionist or hepatologist based on the clinical diagnosis and treatment routine. The administration dose in the instructions for use for current DAAs marketed in China Mainland unnecessary to combine with any IFN is shown but not limited as follows: Sofosbuvir, Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir, Daclatasvir, Asunaprevir, Elbasvir/Grazoprevir, Sofosbuvir/Velpatasvir and Ledipasvir/Sofosbuvir.
RECRUITING
Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
RECRUITING
Huashan Hospital, Shanghai
RECRUITING
Shanghai Public Health Clinical Center, Shanghai
RECRUITING
The Second Hospital of Nanjing, Nanjing
RECRUITING
Nanjing Drum Tower Hospital, Nanjing
RECRUITING
Jiangsu Province Hospital, Nanjing
RECRUITING
Changzhou Third People's Hospital, Changzhou
RECRUITING
Wuxi No. 5 People's Hospital, Wuxi
RECRUITING
The Fifth People's Hospital of Suzhou, Suzhou
RECRUITING
The First Hospital of Jiaxing, Jiaxing
RECRUITING
Hwa Mei Hospital, Ningbo
Collaborators (1)
Gilead Sciences
INDUSTRY
Tigermed Consulting Co., Ltd
INDUSTRY
Qing XIe
OTHER